Is a 40 mg dose of enalapril (ACE inhibitor) available?

Is a 40 mg Dose of Enalapril Available?

Yes, a 40 mg daily dose of enalapril is available and FDA-approved, administered as 20 mg twice daily for both hypertension and heart failure. 1

FDA-Approved Dosing Ranges

The FDA label explicitly states that the usual dosage range for hypertension is 10 to 40 mg per day, administered in a single dose or two divided doses 1. For heart failure, the FDA specifies that the maximum daily dose administered in clinical trials was 40 mg in divided doses 1.

• Hypertension: The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily, even in patients with renal impairment (creatinine clearance ≤30 mL/min) 1.
• Heart failure: In placebo-controlled survival studies, patients were titrated as tolerated up to 40 mg administered in two divided doses (20 mg twice daily) 1.

Evidence-Based Target Doses from Clinical Trials

Major randomized controlled trials established the efficacy of enalapril at doses up to 40 mg daily:

• CONSENSUS trial (1987): Used enalapril 2.5 to 40 mg per day in patients with severe heart failure (NYHA Class IV), demonstrating a 40% reduction in six-month mortality compared to placebo 2, 3.
• V-HeFT II and SOLVD trials: Targeted enalapril 10 mg twice daily (20 mg total daily), with mean daily doses of 15.0–18.4 mg 2.
• The 2016 ESC Heart Failure Guidelines list enalapril's target dose as 10–20 mg twice daily (20–40 mg total daily) based on these landmark trials 4.

Guideline Recommendations for Maximum Dosing

European Society of Cardiology (2005,2016): Recommends a maintenance dose of 10 mg twice daily (20 mg total) for heart failure, with acknowledgment that the CONSENSUS trial used up to 40 mg daily 2, 4, 2.

Canadian Heart Failure Guideline (2006): Recommends a target dose of 10 mg twice daily (20 mg total) for chronic heart failure, noting that higher doses may be required in some individuals 5.

The 2018 Hypertension Canada Guidelines do not specify an upper limit for enalapril but recommend ACE inhibitors as first-line monotherapy for hypertension 6.

Clinical Evidence Supporting Higher Doses

Research demonstrates that higher enalapril doses provide superior outcomes:

• A 1999 within-patient comparison study showed that 40 mg daily improved exercise capacity and reduced neurohormonal stimulation (ANP, BNP, norepinephrine) compared to 10 mg daily 7.
• A 1996 randomized trial in severe heart failure found that 40 mg daily (20 mg twice daily) improved NYHA functional class more than 10 mg daily, despite similar hemodynamic effects 8.
• A 2000 study demonstrated that recommended doses of ACE inhibitors do not fully inhibit ACE in heart failure, and greater inhibition is achieved at twice the recommended doses 9.

Practical Titration to 40 mg Daily

Starting dose: 2.5 mg once daily for heart failure or 5 mg once daily for hypertension 1.

Titration schedule: Double the dose every 1–2 weeks if tolerated, progressing through 2.5 → 5 → 10 → 20 → 40 mg daily 2, 4, 2.

Monitoring: Check blood pressure, serum creatinine, and potassium 1–2 weeks after each dose increase 2.

Safety Thresholds That Prevent Dose Escalation to 40 mg

• Systolic blood pressure <80 mm Hg: Contraindication to further dose increase 5.
• Serum creatinine ≥3 mg/dL or creatinine clearance ≤30 mL/min: Initial dose should be 2.5 mg daily; maximum 40 mg daily is still permitted but requires close monitoring 1.
• Serum potassium >5.0 mEq/L: Avoid concomitant potassium supplements or potassium-sparing diuretics 1.
• Bilateral renal artery stenosis or history of angioedema: Absolute contraindications to any enalapril dose 2, 5.

Common Pitfall: Confusing Total Daily Dose with Single-Dose Strength

The 40 mg daily dose is administered as 20 mg twice daily, not as a single 40 mg tablet 1, 3. The FDA label consistently refers to "40 mg in divided doses" for heart failure 1.

A 1999 hypertension study demonstrated that after long-term treatment with 40 mg daily (20 mg twice daily), the dose could be reduced as much as 8-fold to 5 mg daily without loss of blood pressure control or left ventricular benefits, suggesting that initial high-dose therapy may allow subsequent dose reduction 10.

Hyperkalemia Risk with Combination Therapy

When enalapril 40 mg daily is combined with aldosterone antagonists (spironolactone, eplerenone), close potassium monitoring is mandatory. A 2026 pediatric case report documented severe hyperkalemia (8.9 mEq/L) when enalapril and spironolactone were used concomitantly, resolving within 72 hours of spironolactone discontinuation 11. This risk applies to adults as well and necessitates frequent electrolyte checks when combining these agents 2.